Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company based in Laval, Quebec, Canada. Valeant develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. Valeant owns Bausch & Lomb, one of the largest manufacturers of contact lenses.
Valeant grew quickly with a series of mergers and acquisitions under the leadership of J. Michael Pearson and for a short period of time in 2015 was the most valuable company in Canada. Valeant was described as a platform company that grows by systematically acquiring other companies. Valeant acquired Salix Pharmaceuticals for $14.5 billion in 2015. Valeant tried to acquire Actavis and Cephalon and merge with Allergan, but failed.
In 2015–2016 the company was involved in a controversy about drug price hikes and the use of a specialty pharmacy for the distribution of its specialty drugs. The company's stock price plummeted nearly 90 percent since the peak. Valeant reversed the price hikes and ended cooperation with specialty pharmacy Philidor Rx Services and Walgreens took over distribution.
| Products | Xifaxan Uceris Arestin Jublia Solodyn Ziana Acanya Atralin Retin-A Micro Microsphere Onexton Elidel Glumetza Wellbutrin XL Isuprel Xenazine Nitropress Cuprimine Targretin Zovirax Syprine |
|---|---|
| Subsidiaries | Bausch & Lomb Salix Pharmaceuticals Medicis Pharmaceutical Solta Medical Dendreon OraPharma Obagi |
| Key people | Joseph C. Papa (Chairman and CEO), Paul Herendeen (CFO), Milan Panić (Founder) |
| Traded as | NYSE: VRX TSX: VRX S&P/TSX 60 component |
| Operating income | -US$0.566 billion (2016) |
NPS is a customer loyalty metric that measures customers’ willingness to not only return for another purchase or service but also make a recommendation to their family, friends or colleagues.
It is a powerful and effective technique, which can greatly increase a company's revenue if used properly.
The main advantages of NPS are close correlation with a company's growth and easy collection, interpretation and communication of the data.
Yes, it is.
Net Promoter Score is a number from -100 from 100.
Scores higher than 0 are typically considered to be good and scores above 50 are considered to be excellent.
The industry average for Health Care / Major Pharmaceuticals is 0.
The final Net Promoter Score of a company strongly depends on a context in which the satisfaction is measured.
Consider an example: If Valeant Pharmaceuticals International, Inc. sends out NPS surveys immediately after purchase, they are tracking their customers' initial excitement and the checkout experience.
On the other hand, if they survey their customers a few weeks after the purchase they are also tracking how satisfied their customers are with their products and services over time.
Therefore, comparing the NPS score of Valeant Pharmaceuticals International, Inc. with your own without any further context is not that useful.
What is extremely useful though, is using the NPS methodology to track the satisfaction of your customers over time. That's where Customer.guru comes in.
How are your customers satisfied depending on:
We have estimated the Net Promoter Score of Valeant Pharmaceuticals International, Inc. based on the publicly available information
including the sentiment of the company-related tweets, 3rd party reviews, and Alexa ratings.
Do you think this information is incorrect? Report incorrect information. Do you have more accurate data? Submit NPS score.